Phase 2 N=357 A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Tumors
Primary: Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib — 20; 20 milligram (mg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=90 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
Diabetes Mellitus, Type 2
Primary: Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment — -0.18; 0.14; -0.08; -0.03 mg/kg.min
Phase 2 N=47 Cyclosporine For The Treatment Of COVID-19(+)
SARS (Disease)
Primary: WHO(World Health Organization) COVID-19 Clinical Severity Scale — 2; 2 units on a scale
Phase 1 N=40 Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Immune Response — 132.7; 192.8 Total number of expanded clones
N/A N=28 Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
Opioid-use Disorder
Primary: Number of Participants With Adverse Events and/or Serious Adverse Events — 2 Participants
N/A N=21 Managing Pain and Cognitions in Older Adults With Mild Cognitive Impairment or Memory Related Problems and Chronic Pain
Chronic Pain · Mild Cognitive Impairment · Older Adults
Primary: Client Satisfaction Questionnaire 3-Item (CSQ-3): Number of Participants With Scores Above and Below Scale Midpoint — 8; 9; 0; 1 Participants
N/A N=292 Wearable Technology in Endoscopy
Healthy
Primary: Recorded Tachycardia Events — 9; 3; 22 Events
N/A N=372 A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy
Polypharmacy · Care Transitions · Geriatric Syndromes
Primary: Total Number of Medications — 15; 16; 13; 15 Medications — p=0.017
N/A N=57 Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers
Alzheimer Dementia · Caregiver · Dementia Alzheimers
Primary: Number of Participants Attending at Least 6 Telephone Sessions — 27; 23; 50 Participants
N/A N=7,630 A Randomized Trial of a BE-EHR Module to Guide the Care of Older Adults With Diabetes
Diabetes
Primary: Number of Participants Who Are CW-Compliant and CW-Noncompliant — 412; 704; 1232; 1854 Participants
N/A N=80 Exergame Study for Family Caregivers
Sedentary Lifestyle
Primary: Percent Change in Steps — 4.68; 4.77; 11.87; 2.69 Percent Change of Steps from Baseline — p=.49
Phase 2 N=130 A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Sickle Cell Disease
Primary: Overall Incidence of Treatment Emergent Severe Adverse Events (SAE) — 15; 20 Participants — p=0.19
Phase 2 N=52 A Study of the Relationship Between Disulfiram and Cocaine Self-administration.
Cocaine Addiction
Primary: Cocaine Self-administration — 2.5; 4.8 cocaine choices/participant
N/A N=560 Telemedicine Control Tower for the Post-Anesthesia Care Unit
Elective Surgery
Primary: Difference in Time to PACU Discharge Determination From Observation to Interaction Phase — 84.5; 91.5 Minutes
Phase 3 N=458 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Vitiligo
Primary: Time to Relapse (Defined as <F-VASI75) — NA; NA days — p=0.0414